Marinus Pharmaceuticals, Inc. financial data

Symbol
MRNS on Nasdaq
Industry
Pharmaceutical Preparations
Location
5 Radnor Corporate Center Suite 500, 100 Matsonford Rd, Radnor, PA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 383 % -57.7%
Quick Ratio 10.6 % +240%
Debt-to-equity 7.82K % +4907%
Return On Equity -7.94K % -24292%
Return On Assets -100 % -689%
Operating Margin -447 % +6.29%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 55.1M shares +8.84%
Common Stock, Shares, Outstanding 55M shares +8.61%
Entity Public Float 545M USD +204%
Common Stock, Value, Issued 55K USD +7.84%
Weighted Average Number of Shares Outstanding, Basic 57.1M shares +8.59%
Weighted Average Number of Shares Outstanding, Diluted 57.1M shares +8.59%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 30.3M USD +16.6%
Revenue from Contract with Customer, Excluding Assessed Tax 12.7M USD
Research and Development Expense 95.1M USD +5.89%
General and Administrative Expense 48.9M USD +76%
Costs and Expenses 165M USD +10.5%
Operating Income (Loss) -135M USD -9.24%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -35.8M USD -7.04%
Income Tax Expense (Benefit) -1.54M USD
Net Income (Loss) Attributable to Parent -149M USD -439%
Earnings Per Share, Basic -2.66 USD/shares -1167%
Earnings Per Share, Diluted -2.66 USD/shares -1167%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 64.7M USD -49.4%
Cash, Cash Equivalents, and Short-term Investments 113M USD
Accounts Receivable, after Allowance for Credit Loss, Current 3.44M USD -34.4%
Inventory, Net 4.87M USD +82.2%
Assets, Current 81.9M USD -57.9%
Property, Plant and Equipment, Net 3.72M USD -5.54%
Operating Lease, Right-of-Use Asset 700K USD -36.4%
Other Assets, Noncurrent 1.48M USD -44.2%
Assets 87.1M USD -56.7%
Accounts Payable, Current 6.24M USD +171%
Employee-related Liabilities, Current 3.78M USD -31.2%
Accrued Liabilities, Current 15.2M USD -14.9%
Liabilities, Current 35.9M USD +40.1%
Operating Lease, Liability, Noncurrent 211K USD -78.7%
Liabilities 134M USD -6.56%
Accumulated Other Comprehensive Income (Loss), Net of Tax -20K USD
Retained Earnings (Accumulated Deficit) -646M USD -30%
Stockholders' Equity Attributable to Parent -47.3M USD -183%
Liabilities and Equity 87.1M USD -56.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -37.5M USD +9.69%
Net Cash Provided by (Used in) Financing Activities 257K USD
Net Cash Provided by (Used in) Investing Activities 20.9M USD
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 55M shares +8.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -16.3M USD +82.6%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 64.7M USD -49.4%
Interest Paid, Excluding Capitalized Interest, Operating Activities 2.67M USD +23.9%
Deferred Tax Assets, Valuation Allowance 167M USD +35.4%
Deferred Tax Assets, Gross 168M USD +35.4%
Operating Lease, Liability 989K USD -40.8%
Depreciation 131K USD -16.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -149M USD -436%
Lessee, Operating Lease, Liability, to be Paid 1.06M USD -43.9%
Property, Plant and Equipment, Gross 5.74M USD +0.93%
Operating Lease, Liability, Current 778K USD +14.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 662K USD -21.2%
Lessee, Operating Lease, Liability, to be Paid, Year One 641K USD -23.7%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 74K USD -67.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 642K USD -23.6%
Deferred Tax Assets, Operating Loss Carryforwards 72.8M USD +25.4%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 599M USD +8.01%
Share-based Payment Arrangement, Expense 18M USD +15.4%
Interest Expense 17.1M USD +30.2%